Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Center for Prevention of Progression cares for patients diagnosed with – or at high risk for – precursor conditions of hematologic malignancies, including:
In CHIP, some blood-forming stem cells acquire leukemia-associated mutations and contribute more than their share to blood cell development. Individuals with CHIP don't have symptoms or obvious abnormalities in their blood counts, but Dana-Farber research has shown CHIP to be associated with 10-fold increased risk for blood cancers such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs). The rate of transformation from CHIP to blood cancers is around 1% per year.
Sometimes patients with low blood counts undergo further evaluation, including bone marrow and blood tests, but no specific cause is found for the low blood counts. These patients have unexplained low blood counts or "idiopathic cytopenias of undetermined significance" (ICUS) and the risk of blood cancer development is variable. The subset of these patients who have mutations similar to those observed in CHIP are diagnosed with "clonal cytopenia of undetermined significance" (CCUS). The risk of developing acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) is higher in CCUS than in CHIP. Compared to general population, patients with CCUS have a 13-fold increased risk of blood cancer development.
MGUS is a condition in which there are abnormal plasma cells in the bone marrow, but there is no cancer. The abnormal plasma cells produce monoclonal (M) protein. In most patients, the amount of M protein stays the same, and there are no symptoms or problems.
In some patients, MGUS may later become a more serious condition or cancer, such as multiple myeloma, lymphoma, or Waldenström's macroglobulinemia, or AL amyloidosis.
Smoldering myeloma is a precursor condition in which high concentrations of abnormal plasma cells are found in the bone marrow and secrete monoclonal (M) proteins and/or free light-chains (FLCs). Smoldering myeloma may progress to multiple myeloma.
Monoclonal B-cell lymphocytosis (MBL) is very common in people older than 50 years and can be a precursor condition to chronic lymphocytic leukemia (CLL). Most
people who develop CLL have had MBL, and about 1 percent per year will convert to CLL. MBL also predisposes to non-Hodgkin lymphoma.
In L-CH, blood-forming stem cells may have lymphoma or CLL-associated mutations in patients without any signs or symptoms of a blood cancer. Individuals with L-CH have an increased risk of developing lymphoid blood cancers, including lymphoma and CLL.
Center for Prevention of Progression Appointments